✨ Free AI Report
Can-Fite BioPharma Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Can-Fite BioPharma Ltd.
Company Research

Can-Fite BioPharma Ltd.: Business Overview, Financials & Competitive Analysis

Can-Fite BioPharma is a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is advancing multiple candidates through clinical dev...

Analyst-debate audio for Can-Fite BioPharma Ltd.

AskCyborg analysts argue the bull and bear cases for Can-Fite BioPharma Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with promising oncology pipeline facing capital constraints but positioned for near-term Phase III interim...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-stage Oncology and Immunology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Can-Fite BioPharma Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Can-Fite BioPharma Ltd. Overview

Pro stress-test →

Can-Fite BioPharma is a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is advancing multiple candidates through clinical development with particular focus on rare cancers and liver disease, addressing multi-billion-dollar unmet medical needs.

Strategic Profile

Pro stress-test →

The company is currently enrolling patients in a pivotal Phase III clinical study evaluating Namodenoson for advanced hepatocellular carcinoma in patients with Child-Pugh B7 liver function, a patient population with no approved therapies currently available. The company's lead drug candidate Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. The company has orphan drug and fast-track designations from the FDA for multiple programs.

Competitive Landscape

Pro stress-test →

Can-Fite competes in the oncology and immunology spaces. Competitors in liver cancer include companies developing other HCC treatments, though Can-Fite's focus on the Child-Pugh B7 patient population addresses an underserved market. In psoriasis and inflammatory disease, competition includes established players and other biotech firms. The company's advantage lies in its novel A3 adenosine receptor agonist mechanism and clinical proof-of-concept in multiple indications.

Industry Context

Can-Fite BioPharma Ltd. operates in Biopharmaceutical / Clinical-stage Oncology and Immunology.

Key facts

Founded: 1994 · Headquarters: Ramat Gan, Israel

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Can-Fite BioPharma Ltd..

  • In January 2026, patient enrollment was completed in a Phase 2a pancreatic cancer clinical trial of Namodenoson, with efficacy data expected in Q3 2026
  • A patient with advanced liver cancer treated with Namodenoson achieved 9-year overall survival with complete response, including cancer-free status and normal liver function
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Patient with decompensated liver cirrhosis successfully underwent transplantation following Namodenoson treatment
  • January 2026Completed patient enrollment in Phase 2a pancreatic cancer trial with safety profile demonstrated
  • +2 moreTrack every material event for Can-Fite BioPharma Ltd. as it happens. Explore monitoring →
Get alerted when Can-Fite BioPharma Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Sorafenib and other tyrosine kinase inhibitorsEstablished HCC treatments for other patient populations→Biologics for psoriasis/inflammatory diseaseTNF inhibitors and IL-inhibitors for inflammatory diseases→Small molecule oncology programsOther clinical-stage cancer candidates→

Compare Can-Fite BioPharma Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Can-Fite BioPharma Ltd. operates in Biopharmaceutical / Clinical-stage Oncology and Immunology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-stage Oncology and Immunology research →
NEW · MCP server

Ask your AI assistant about Can-Fite BioPharma Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Can-Fite BioPharma Ltd. and its top competitor on Cyborg Score”
“What did Can-Fite BioPharma Ltd. do this quarter?”
“Is Can-Fite BioPharma Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Can-Fite BioPharma Ltd. do?+
Can-Fite BioPharma is a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases. The company is advancing multiple candidates through clinical dev...
What is Can-Fite BioPharma Ltd.'s Cyborg Score?+
Can-Fite BioPharma Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Can-Fite BioPharma Ltd.'s main competitors?+
Named competitors include Sorafenib and other tyrosine kinase inhibitors, Biologics for psoriasis/inflammatory disease, Small molecule oncology programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Can-Fite BioPharma Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Can-Fite BioPharma Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Can-Fite BioPharma Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score